Filing summary
Entity mismatch: The supplied filing is Inpixon’s Form 10-Q, not a filing identifying XTI Aerospace, Inc. The summary below reflects the filing text provided. It covers the quarter and nine months ended September 30, 2018; financial statement amounts are in thousands unless noted.
Business context and reporting period
Inpixon provided indoor positioning analytics (IPA) products and services, including location-based analytics and SaaS offerings. On August 31, 2018, it spun off its value-added reseller business, Sysorex, Inc.; Sysorex’s results are presented as discontinued operations. The company also held an approximately 82.5% interest in Sysorex India.
Financial results and liquidity
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Revenue | $940 | $871 | $2,627 | $3,007 |
| Gross profit / margin | $642 / 68% | $604 / 69% | $1,809 / 69% | $2,017 / 67% |
| Operating loss | $(3,317) | $(4,695) | $(11,579) | $(12,066) |
| Net loss | $(5,180) | $(14,641) | $(17,278) | $(27,129) |
| Loss from discontinued operations | $(1,785) | $(9,754) | $(4,778) | $(13,946) |
| Adjusted EBITDA loss | $(3,427) | $(3,121) | $(10,881) | $(9,154) |
At September 30, cash was $1,461, working capital was positive $1,093, and total assets and liabilities were $12,991 and $3,964, respectively. Debt was $1,815 short-term and $142 long-term; the Payplant facility had no balance outstanding. Nine-month operating cash use was $23,385, investing cash use was $1,237, and financing provided $25,957. Cash ended the period at $1,461.
Changes versus the prior comparable period
- Q3 revenue increased about 8%, principally from higher IPA product sales; nine-month revenue decreased about 13%, which management attributed mainly to the transition toward subscription/SaaS revenue from prior-period license revenue.
- Gross margin was 68% in Q3 versus 69% a year earlier, and 69% for the nine-month period versus 67%.
- Operating expenses fell 25% in Q3 and 5% year to date, mainly from lower compensation and occupancy costs following staff and office reductions.
- Net loss improved year over year, substantially reflecting lower discontinued-operation losses, including a prior-year goodwill impairment charge. However, adjusted EBITDA loss widened to $10.9 million for the nine months from $9.2 million.
- The balance sheet reflects the Sysorex spin-off and substantial 2018 equity financing; year-over-year comparisons are therefore affected by changes in the consolidated business and share count.
Outlook, risks and unusual items
- Going concern: Management reported substantial doubt about the company’s ability to continue as a going concern. It said current resources and expected financing capacity could fund planned operations through 2018, but additional funds would be needed for the following 12 months. Plans included raising capital, improving operating efficiency, reducing costs, and growing revenue.
- Financing and dilution: 2018 offerings generated approximately $28 million in net proceeds. Preferred-stock and warrant repricing provisions produced substantial deemed dividends. Subsequent to quarter-end, the company issued an unsecured note for $2 million cash, with $2.52 million principal, 10% annual interest, and monthly redemption rights beginning after six months. It also exchanged $1.54 million of a convertible note for shares.
- Nasdaq listing: Inpixon had a minimum-bid-price deficiency and did not expect to cure it within the initial compliance period. It implemented a 1-for-40 reverse stock split effective November 2, 2018, but stated there was no assurance it would regain or maintain listing compliance.
- Legal contingency: A consultant sought at least $1 million less amounts previously paid, alleging fees tied to financing transactions. Inpixon contested the claim; an arbitration hearing was scheduled for December 4–6, 2018. The filing also describes settlements of Sysorex-related matters and an AVT claim, with Sysorex responsible for the specified payments or indemnity.
- Other items: Subsequent to quarter-end, Inpixon recorded $465,000 of expense for shares issued for services. Management cited long sales cycles, early-stage customer adoption, market weakness, depressed share price, and execution challenges. It expected IPA growth but gave no quantified revenue or earnings guidance.
Key facts investors should verify
- Confirm the intended issuer: the filing identifies Inpixon, not XTI Aerospace, Inc.
- Assess the going-concern disclosure against cash burn, available financing, and the company’s need for additional capital.
- Review the October note’s effective financing cost, redemption terms, and potential cash repayment burden.
- Track Nasdaq compliance after the reverse split and any resulting listing notices.
- Check the outcome and financial exposure of the consultant arbitration and confirm the status of Sysorex indemnities and transition-related receivables.
- Reconcile the cash-flow presentation: the financial statements report operating cash use of $23.385 million, while MD&A also describes it as $24.1 million.